Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled “Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker” will be presented by Dr. Chad Tang, M.D., associate professor in the department of genitourinary radiation oncology at The University of Texas MD Anderson Cancer Center (MDACC) on April 28. The abstract presentation number is CT132. MRWS offers substantial advantages for patients compared to more aggressive frontline systemic therapies; how
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Looking at the Narrative for Myriad Genetics After Price Target Revisions and Growth Concerns [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (MYGN) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer SymposiumGlobeNewswire
- Why Myriad Genetics (MYGN) Stock Is Trading Lower Today [Yahoo! Finance]Yahoo! Finance
- How Recent Developments Are Shaping the Myriad Genetics Investment Story [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 11/3/25 - Beat
MYGN
Sec Filings
- 12/12/25 - Form 4
- 11/12/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- MYGN's page on the SEC website